Uroplasty (UPI) & St Jude Medical (STJ) Head to Head Contrast
Uroplasty (NASDAQ: UPI) and St Jude Medical (NYSE:STJ) are both medical devices & implants companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.
This is a summary of recent ratings for Uroplasty and St Jude Medical, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|St Jude Medical||0||0||0||0||N/A|
Institutional and Insider Ownership
82.7% of St Jude Medical shares are owned by institutional investors. 4.8% of St Jude Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Uroplasty and St Jude Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|St Jude Medical||14.14%||19.40%||6.75%|
St Jude Medical pays an annual dividend of $1.24 per share and has a dividend yield of 1.5%. Uroplasty does not pay a dividend. St Jude Medical pays out 54.4% of its earnings in the form of a dividend. Uroplasty has raised its dividend for 6 consecutive years.
Earnings and Valuation
This table compares Uroplasty and St Jude Medical’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|St Jude Medical||N/A||N/A||N/A||$2.28||35.45|
Uroplasty is trading at a lower price-to-earnings ratio than St Jude Medical, indicating that it is currently the more affordable of the two stocks.
St Jude Medical beats Uroplasty on 7 of the 9 factors compared between the two stocks.
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
About St Jude Medical
St. Jude Medical, Inc. is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. The Company’s product categories include tachycardia implantable cardioverter defibrillator systems; atrial fibrillation products (electrophysiology introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems); bradycardia pacemaker systems; vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography imaging products, vascular plugs, heart failure monitoring devices and other vascular accessories); structural heart products (heart valve replacement and repair products and structural heart defect devices); neuromodulation products, and Thoratec products.
Receive News & Stock Ratings for Uroplasty Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty Inc. and related stocks with our FREE daily email newsletter.